Status:

WITHDRAWN

Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly

Lead Sponsor:

University of Medicine and Dentistry of New Jersey

Collaborating Sponsors:

United States Department of Defense

Conditions:

Prostate Cancer

Eligibility:

MALE

75+ years

Brief Summary

The widespread availability of screening coupled with high risks of over diagnosis, over treatment, and a rising risk of dying from competing causes of deaths pose a major challenge for prostate cance...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Diagnosed at age 75 or older.
  • Diagnosed with non-metastatic prostate cancer in 1992-1999.
  • Enrolled in Medicare for the 12 months before diagnosis for an adequate assessment of baseline comorbidity.
  • Enrolled in Medicare Part A and Part B through death or the end of the study period to have an adequate claim history of cancer treatment over the follow-up period.
  • Alive for at least 6 months after cancer diagnosis. This criterion will remove men who are diagnosed at death or who are dying and have severe comorbidities, and are therefore poor candidates for 'aggressive' cancer interventions.
  • Exclusion criteria:
  • Enrolled in Medicare managed care plans during the study period since no Medicare claims are available during the period of enrollment.
  • Have other types of cancer. This criterion will ensure that all cancer therapies identified from the Medicare claims are for prostate cancer exclusively.

Exclusion

    Key Trial Info

    Start Date :

    March 1 2005

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2008

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT00161252

    Start Date

    March 1 2005

    End Date

    December 1 2008

    Last Update

    September 27 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Cancer Institute of New Jersey

    New Brunswick, New Jersey, United States, 08901

    Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly | DecenTrialz